Bio-Thera's Golimumab Secures European Commercialization Deal with STADA; Xingqi Pharma Launches 0.01% Atropine Eye Drops on Alibaba Health
Bio-Thera
Innovative Drug Developer
Xingqi Pharmaceutical
Ophthalmic Drug Research, Development, Production, and Sales
AliHealth
Medical and Health Services Network Service Provider
Innovent
High-end Biologics Developer
Medtronic
Medical Device Manufacturer
In the race for myopia prevention drugs, AliHealth takes the lead.
On May 28, Xingqi Pharmaceutical announced that its 0.01% Atropine Sulfate Eye Drops officially launched for the first time on AliHealth's online pharmacy.
Chinese-produced pharmaceuticals continue to expand overseas.
On May 28, Bio-Thera announced that it has granted STADA the exclusive commercialization rights for its golimumab BAT2506 in the EU, UK, Switzerland, and other parts of Europe, with an upfront payment and milestone payments totaling up to $157.5 million.
Innovent Bio's autoimmune layout enters the harvest period.
Today, Innovent Bio announced that the Phase III clinical study CLEAR-1 of IL-23p19 antibody Picankibart conducted in Chinese subjects with moderate to severe plaque psoriasis has achieved the primary endpoint and all key secondary endpoints.
In the past day, what are the hotspots in the pharmaceutical markets at home and abroad that are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Bio-Thera and STADA Sign Licensing and Commercialization Agreement
On May 28, Bio-Thera announced that it had granted STADA the exclusive commercialization rights for its golimumab BAT2506 in the EU, UK, Switzerland, and other parts of Europe, with an upfront payment and milestone payments totaling up to $157.5 million.
2) Zhejiang East-Asia Pharmaceutical Co.,Ltd.'s Levofloxacin API Passes WHO PQ Certification
On May 28, Zhejiang East-Asia Pharmaceutical Co., Ltd. announced that the company's Levofloxacin API had obtained the CPQ certificate issued by WHO, with the WHO prequalification number WHOAPI-413. The production address is located in Sanmen County, Zhejiang Province, China.
3) Xingqi Pharmaceutical's Atropine Jointly Launched with AliHealth
On May 28, Xingqi Pharmaceutical announced that its 0.01% Atropine Sulfate Eye Drops were officially launched on AliHealth's online pharmacy platform.
/ 02 /
Pharmaceuticals and Medical Devices Dynamics
1) Positive Results from Innovent Bio's IL-23 Monoclonal Antibody Phase III Study for Moderate to Severe Plaque Psoriasis
On May 28, Innovent Bio announced that the IL-23p19 antibody Picankibart reached the primary endpoint and all key secondary endpoints in the Phase III clinical study CLEAR-1 conducted among Chinese subjects with moderate to severe plaque psoriasis.
2) Zelgen Bio's Jaktinib Hydrochloride Tablets Approved for Clinical Trials
On May 28, according to the CDE official website, Zelgen Bio's Jacktinib Hydrochloride Tablets have been approved for clinical trials, intended for the treatment of non-segmental vitiligo patients aged 12 years and above, including adolescents and adults.
3) Bio-Thera's Bevacizumab Approved for Clinical Use
On May 28, according to the CDE official website, Bio-Thera's Bevacizumab was approved for clinical trials, intended to be used in combination with BAT8008 Injection for the treatment of patients with advanced solid tumors.
4) China Resources Jiuxin Pharmaceutical's Sodium Cefpirome Injection Marketing Application Proposed for Priority Review
On May 28, according to the CDE website, China Resources Jiuxin Pharmaceutical's Sodium Ceftobiprole Mesylate for Injection has been granted priority review for its marketing application. Indications: Hospital-acquired pneumonia, excluding ventilator-associated pneumonia; community-acquired pneumonia.
5) Medtronic's Mazor X™️ Stealth Robotic Guidance System for Spine Surgery Launched
Recently, Medtronic announced the successful launch in China of its fully upgraded Mazor X™️ Eagle Spine Surgical Robotic Integrated Platform.
/ 03 /
Overseas Pharmaceutical News
1) Eisai/Biogen Alzheimer's Antibody Drug Approved for Marketing in South Korea
On May 28, Eisai and Biogen announced that the South Korean Ministry of Food and Drug Safety (MFDS) has approved the marketing of lecanemab, a humanized anti-soluble amyloid-beta (Aβ) monoclonal antibody, for the treatment of adults with early (mild) Alzheimer's disease or mild cognitive impairment caused by Alzheimer's disease.
Text / Huang Kai
PS: Welcome to scan the QR code below to add Amino Jun's WeChat for communication.
